Hisamitsu Seiyaku KK header image

Hisamitsu Seiyaku KK

4530

Equity

ISIN JP3784600003 / Valor 761916

Tokyo Stock Exchange (2024-11-21)
JPY 4,284.00+1.18%

Hisamitsu Seiyaku KK
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Hisamitsu Seiyaku KK is a Japanese pharmaceutical company specializing in the development, manufacture, and sale of transdermal drug delivery systems, such as patches.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (14.08.2024):

Net Sales Growth

Hisamitsu Seiyaku KK reported consolidated net sales of 35,810 million yen for the first quarter of the fiscal year ending February 28, 2025, reflecting an 11.6% increase compared to the same period in the previous year. This growth indicates a positive trend in the company's revenue generation.

Operating Profit Decline

Despite the increase in net sales, Hisamitsu Seiyaku KK experienced a decline in operating profit, which fell by 4.9% year-on-year to 4,149 million yen for the first quarter of the fiscal year ending February 28, 2025. This suggests that the company faced higher operating expenses or other challenges impacting profitability.

Profit Attributable to Owners

The profit attributable to owners of the parent company for Hisamitsu Seiyaku KK in the first quarter of the fiscal year ending February 28, 2025, was 5,562 million yen, a slight decrease of 2.7% compared to the same period in the previous year. This indicates a marginal reduction in the net earnings available to shareholders.

Dividend Forecast

Hisamitsu Seiyaku KK has forecasted an annual dividend of 90.00 yen per share for the fiscal year ending February 28, 2025, which includes a commemorative dividend of 4.00 yen for the 90th anniversary of the launch of SALONPAS®. This represents an increase from the previous year's total dividend of 85.00 yen per share.

Comprehensive Income Surge

Comprehensive income for Hisamitsu Seiyaku KK surged by 85.0% year-on-year to 12,025 million yen for the first quarter of the fiscal year ending February 28, 2025. This significant increase was driven by factors such as foreign currency translation adjustments and valuation differences on available-for-sale securities.

Summarized from source with an LLMView Source

Key figures

-6.11%1Y
6.70%3Y
-17.8%5Y

Performance

20.2%1Y
26.7%3Y
28.7%5Y

Volatility

Market cap

2354 M

Market cap (USD)

Daily traded volume (Shares)

100,400

Daily traded volume (Shares)

1 day high/low

4297 / 4233

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Aurora Cannabis Inc
Aurora Cannabis Inc Aurora Cannabis Inc Valor: 132838450
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.50%CAD 6.05
Heidelberg Pharma AG
Heidelberg Pharma AG Heidelberg Pharma AG Valor: 24937540
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.76%EUR 2.23
Emeis
Emeis Emeis Valor: 132546338
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-6.89%EUR 5.21
PACS Group Inc
PACS Group Inc PACS Group Inc Valor: 133777092
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.06%USD 16.55
Meta Data Limited
Meta Data Limited Meta Data Limited Valor: 136954714
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-77.97%EUR 0.56
Paul Hartmann AG
Paul Hartmann AG Paul Hartmann AG Valor: 1547181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.34%EUR 209.00
Shield Therapeutics PLC
Shield Therapeutics PLC Shield Therapeutics PLC Valor: 29778101
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
11.11%GBP 0.029
AtriCure Inc
AtriCure Inc AtriCure Inc Valor: 2134051
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.15%USD 35.73
GeneDx Holdings Corp
GeneDx Holdings Corp GeneDx Holdings Corp Valor: 126808031
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
9.21%USD 78.71
Neumora Therapeutics Inc
Neumora Therapeutics Inc Neumora Therapeutics Inc Valor: 129329732
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.52%USD 9.74